Skin Aging
Conditions
Interventions
Comparison group 1: 15 volunteers will receive 100mg of coenzyme Q10 orally, once a day. Comparison group 2: 15 volunteers will receive 200mg of coenzyme Q10 orally, once a day. Control group: 15 volu
SP6.051.227
Sponsors
Universidade de São Paulo (USP)
Universidade de São Paulo (USP)
Eligibility
Sex/Gender
Female
Age
60 Years to 80 Years
Inclusion criteria
Inclusion criteria: Healthy women; elderly aged between 60 and 80 years old; phototypes I, II or III on the Fitzpatrick scale; in good physical and mental health; able to follow study instructions; with the desire and availability to attend the evaluations and exam collections on predetermined dates; who sign the informed consent form.
Exclusion criteria
Exclusion criteria: Users of drugs such as statins, beta-blockers, phenothiazines, tricyclic antidepressants, antiplatelet agents and warfarin anticoagulants; hypersensitivity or intolerance to coenzyme Q10; intestinal absorption disorders; diagnoses of kidney and liver diseases; history of collagenosis; current neoplasms.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Expected outcome 1: As a primary outcome it is expected to find an increase in the area of ??collagen fibers, verified through microscopic quantification of the skin biopsy samples, from the increase in the area marked by the color of Picrosirius red, before and after 12 weeks of supplementation. | — |
Secondary
| Measure | Time frame |
|---|---|
| Expected outcome 2: As a secondary outcome, it is expected to find an increase in the area of ??elastic fibers, verified through microscopic quantification of the skin biopsy samples, from the increase in the area marked by Weigert stain, before and after 12 weeks of supplementation.;Expected outcome 3: As a secondary outcome, it is expected to improve the viscoelasticity of the skin in the forearm region using the Cutometer equipment - dual MPA 580 (CK Eletronic), before and after 12 weeks of supplementation. ;Expected outcome 4: As a secondary outcome, it is expected to see a reduction in transepidermal water loss in the skin of the forearm region, assessed with the Tewameter - TM 300 (CK Eletronic), before and after 12 weeks of supplementation.;Expected outcome 5: As a secondary outcome, it is expected to see improvement in skin hydration in the forearm region, using the Corneometer probe - CM 825 (CK Eletronic), before and after 12 weeks of supplementation.;Expected outcome 6: As a secondary outcome, it is expected to verify the improved quality of life and self-assessment of patients assessed using questionnaires. The quality of life questionnaires for patients with adapted dermatological diseases and the Likert scale will be used to check the patients' self-assessment, before and after 12 weeks of supplementation. | — |
Countries
Brazil
Contacts
Public ContactJosé Antônio Sanches Junior
Universidade de São Paulo (USP)
Outcome results
None listed